Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.
about
Emerging treatment options for nasopharyngeal carcinomaPhase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinomaMulti-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapyOncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis.Downregulation of Ras association domain family member 6 (RASSF6) underlies the treatment resistance of highly metastatic nasopharyngeal carcinoma cells.MiR-145 inhibits metastasis by targeting fascin actin-bundling protein 1 in nasopharyngeal carcinomaHigh expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma.Sp1 is over-expressed in nasopharyngeal cancer and is a poor prognostic indicator for patients receiving radiotherapyExpression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinomaFunctional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma.In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles.ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylationEpstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells.Extracellular serglycin upregulates the CD44 receptor in an autocrine manner to maintain self-renewal in nasopharyngeal carcinoma cells by reciprocally activating the MAPK/β-catenin axisTargeting tumor hypoxia in nasopharyngeal carcinoma.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.Evaluation of 7th Edition of AJCC Staging System for Nasopharyngeal Carcinoma.Outcomes of Saudi Arabian Patients With Nasopharyngeal Cancer Treated With Primarily Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy.Investigational drugs for nasopharyngeal carcinoma.Tetrandrine Induces Apoptosis of Human Nasopharyngeal Carcinoma NPC-TW 076 Cells through Reactive Oxygen Species Accompanied by an Endoplasmic Reticulum Stress Signaling Pathway.Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma.Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factorInhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma.Proteomic profiling between CNE-2 and its strongly metastatic subclone S-18 and functional characterization of HSP27 in metastasis of nasopharyngeal carcinoma.Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer.Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
P2860
Q26995560-B5DF1DC0-BD54-4D8B-B748-ACC41B35DF16Q33428455-383DCE21-3786-4B54-9ACD-72F865D5B072Q33439361-ACF86E34-3832-438C-A9E2-E3A074F35D99Q34074410-BCDD4637-9DC7-4FDC-8B0A-118A471B0C86Q35018650-51FB9DF1-0010-481B-8E1B-DBAF2091CD92Q35080861-2930BA58-F9F2-463D-BE8B-897F6DD88CC4Q35207555-51DA365E-22DE-4C21-A04D-40891453302FQ35225191-485EBC2F-A5C9-4A7F-8116-8BD26217AE0BQ35583857-F1CFE84E-D50D-4911-9FD1-287587E017A2Q35919206-66DD025B-7F59-4634-A640-308F8ECAF58AQ36109579-5F683433-E38F-4224-9D7B-FA32AF998074Q36121338-12CADACC-E858-4E5A-BE49-10EE51A990E3Q36278144-9E177DB1-4252-40DD-BC40-7880D335A497Q36766842-313051E6-BDC2-46CC-9F54-50EE66B5718CQ36915011-282CAE11-72BB-442C-85A8-58E349534E0CQ36977432-57C18156-54FD-48A3-9F62-18DFBFA288AFQ36997612-8C80EF9A-FF52-47DB-9A01-6E70E510F946Q37086155-CDDB2565-BFEC-4F84-A757-1C12C5F8A672Q37225382-E26E789D-4093-407A-902B-25F8E73A24FDQ37350214-B7B31E08-0876-4346-AC1F-B4733501BC3BQ37603302-EAFCF080-4B6C-4AB8-A67E-27E78E1A160FQ37959387-B5053750-2B00-4CC1-90B7-7B48932F5E8EQ38385856-69B9D9E3-E806-45F9-8BE9-DA469B3CD8A0Q38600570-25337A8A-2D0E-405F-AE21-88DAF04194C2Q38642001-1F2E466A-9601-448E-B027-3DFF3570AEA6Q38674598-9580E09B-B7DE-4184-8984-411BA036AADBQ38690528-A54C3A2D-50D2-48AC-ADA8-3101B11FEA27Q38740290-FA0CB717-4F96-4AD7-9113-288C74D7CF79Q38821356-8C570FBC-48FA-4002-A465-96569ED31877Q38824800-8036EB8A-1392-4E30-8FF0-9C4535C62987Q39069493-984BB331-D2F4-434F-A4CD-BB82549EB409Q39246432-0326C8D4-BA60-4DCB-99A1-E6423DE9D302Q39381467-6C8C073F-C692-48B8-AC3F-E51E412F1FB7Q39456193-BBD3FEAF-CF04-4FA1-A2ED-372166E2A023Q39515451-5689F2F0-42A8-4595-80FE-D850B87B4A0CQ39704048-C793104D-805E-4391-8705-BE575953FAD4Q39922380-19A365EE-1B18-4B74-8F59-BDA59F867641Q40109785-9D349100-5DD3-4673-AE31-67835ABE5018Q40172727-F7BCEC5E-A022-4B87-820B-24B82C3E3A24Q40458882-C8A61C99-E27C-420A-A456-197BFE8F26AC
P2860
Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic approach to improving ...... current and future directions.
@en
Systemic approach to improving ...... current and future directions.
@nl
type
label
Systemic approach to improving ...... current and future directions.
@en
Systemic approach to improving ...... current and future directions.
@nl
prefLabel
Systemic approach to improving ...... current and future directions.
@en
Systemic approach to improving ...... current and future directions.
@nl
P2860
P1433
P1476
Systemic approach to improving ...... current and future directions
@en
P2093
Edwin P Hui
P2860
P304
P356
10.1111/J.1349-7006.2008.00836.X
P577
2008-05-21T00:00:00Z